From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Monoclonal antibody
TypeWhole antibody
Clinical data
ATC code
  • none
CAS Number
  • none
Chemical and physical data
Molar mass145.2 kg/mol g·mol−1

Lirilumab (INN) is a human monoclonal antibody designed for the treatment of cancer.[1][2] It binds to KIR2DL1/2L3.[3]

This drug was developed by Innate Pharma and is licensed to Bristol-Myers Squibb.

Clinical trials[edit]

A phase 2 clinical trial for acute myeloid leukemia (AML)[4] was terminated early ("failed") in 2017.[5]

It was registered for a trial for squamous cell carcinoma of the head and neck (SCCHN),[6] but it may be abandoned.[7]

As of November 2017 nine clinical trials of lirilumab are registered as active.[8]


  1. ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Lirilumab, American Medical Association.
  3. ^ Romagné et al., Blood 2009 Preclinical characterization of 1-7F9, a novel human anti–KIR receptor therapeutic antibody that augments natural killer–mediated killing of tumor cells
  4. ^ Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR) (EFFIKIR)
  5. ^ Innate Pharma Leukemia Candidate Lirilumab Fails Phase II Trial. Feb 2017
  6. ^ Adjuvant Nivolumab and Lirilumab in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and Neck
  7. ^ Bad news for Innate Pharma as BMS-backed drug stumbles nov 2017
  8. ^ lirilumab trials